trending Market Intelligence /marketintelligence/en/news-insights/trending/kuuabfgjf2xeew0l57gn9w2 content esgSubNav
In This List

Gene therapy focused Genprex prices IPO

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Gene therapy focused Genprex prices IPO

Genprex Inc. priced its IPO of 1,280,000 common shares at $5 apiece.

Network 1 Financial Securities Inc. is acting as the sole book-running manager for the offering which is expected to close on April 3.

The Austin, Texas-based company, which is developing a therapy for lung cancer, is listing on Nasdaq under the symbol 'GNPX.'

The IPO's underwriters can buy up to an additional 192,000 shares from the company.